



CDK2 (Phospho-Thr160) Antibody

#11133

Catalog Number: 11133-1, 11133-2

Amount: 50 μ g/50 μ l, 100 μ g/100 μ l

Swiss-Prot No. : P24941

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg^{2+} and Ca^{2+}), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at $-20^{\circ}C$ /1 year

Immunogen: The antiserum was produced against synthesized phosphopeptide derived from human CDK2 around the phosphorylation site of threonine160 (T-Y-T^P-H-E).

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.


Specificity/Sensitivity: CDK2 (phospho-Thr160) antibody detects endogenous levels of CDK2 only when phosphorylated at threonine 160.

Reactivity: Human, Mouse, Rat

Applications:


Predicted MW: 34kd

WB: 1:500~1:1000 IHC: 1:50~100 IF:1:100~1:200



Peptide + - -

Western blot analysis of extracts from A2780 cells (Lane 1 and 2) and MDA-MB-435 cells (Lane 3), using CDK2 (phospho-Thr160) antibody (#11133).



P-Peptide - +

Immunohistochemical analysis of paraffin-embedded

human breast carcinoma tissue, using CDK2 (phospho-Thr160) antibody (#11133)

Background :

Involved in the control of the cell cycle. Interacts with cyclins A, B1, B3, D, or E. Activity of CDK2 is maximal during S phase and G2.

References:

- Ukomadu C, et al.(2003) J Biol Chem; 278(7): 4840-6.
Morris MC, et al.(2002)J Biol Chem; 277(26): 23847-53.
Brown NR, et al.(1999)J Biol Chem; 274(13): 8746-56.
Liu Y, et al.(2004) J Biol Chem; 279(6): 4507-14.